Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|October 28, 2021
Daily OTC Pearl: Tussin DM (Dextromethorphan and Guaifenesin)
Author(s)Saro Arakelians, PharmD
Tussin DM helps loosen phlegm and thin bronchial secretions to help drain bronchial tubes.
Advertisement
OTC/Lifestyle Pearl of the Day: Tussin DM (dextromethorphan and guaifenesin)
Indication: Tussin DM is used to treat cough and chest congestion caused by minor throat and bronchial irritations, the
Insight:
- Tussin DM helps loosen phlegm (mucus) and thin bronchial secretions to help drain bronchial tubes.
- Tussin DM will not treat a cough that is caused by
smoking . - Do not use Tussin DM if you have used an
MAO inhibitor in the past 14 days, such asisocarboxazid ,linezolid ,methylene blue injection,phenelzine ,rasagiline ,selegiline , ortranylcypromine . - Dosing: The recommended dose of Tussin DM is 10 ml every 4 hours for adults and children 12 years of age and older. Do not take more than 6 doses in any 24-hour period. Tussin DM is not intended for use in children under 12 years of age.
- Adverse effects may include mood changes, severe headache, dizziness, anxiety, drowsiness, sleep problems, insomnia, diarrhea, and feeling nervousness.
Sources:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5